milrinone
Phase 1- Indications
- Heart failure with preserved ejection fraction
Company intelligence / Profile preview
Cardiora Pty Ltd
Melbourne, Victoria, Australiapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Early studies indicate CRD-102 helps ease symptoms of end stage heart failure including shortness of breath, fluid build up, and exercise intolerance. Preliminary evidence shows patients taking CRD-102 are able to walk further and undertake general activity without symptoms including shortness of breath and fatigue.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecules (oral medicine)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Cardiora Pty Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cardiora Pty Ltd.